Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of relugolix in Japanese patients with hormone-naive non-metastatic prostate cancer
NCT02141659Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2014
- Primary completion
- Apr 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relugolix in prostate cancer (PCa) (6 cohorts), sponsored by Takeda. Primary endpoints: Number of Participants With Dose-limiting Toxicities at Day 28, Number of Participants Reporting One or More Treatment-emergent Adverse Event at Day 712 and 3 more. Started May 2014; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02141659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141659.